Key Quantitative Figures
- Number of equity shares allotted: 38,442
- Face value per share: ₹1
- Exercise price per share: ₹860.00
- Premium per share: ₹859.00
- Pre-allotment paid-up share capital: 41,30,45,091 equity shares
- Post-allotment paid-up share capital: 41,30,83,532 equity shares
- Total issued share capital after allotment: ₹41,30,83,532
- Distinctive number range: 41,30,45,091 to 41,30,83,532 (Both Inclusive)
- ISIN Number: INE634S01028
Dates of Action
- Date of circular resolution: November 19, 2026
- Date of share issue: November 19, 2026
- Previous filing date of statement under Regulation 10(b): September 27, 2023
Parties Involved
- Approving authority: Nomination and Remuneration Committee of the Board of Directors
- Stock exchanges: National Stock Exchange of India Limited (NSE) and BSE Limited (BSE)
- Signing officer: Hitesh Kumar Jain, Company Secretary & Compliance Officer
Capital Structure Impact
The allotment has increased the company's paid-up share capital by 38,442 equity shares, resulting in a dilution of approximately 0.093% of the pre-allotment share capital. The new shares rank pari-passu with existing equity shares of the company.
Additional Details
- Scheme title: Mankind Employee Stock Option Plan 2022
- Company registered office: 208, Okhla Industrial Estate, Phase-III, New Delhi-110020
- No lock-in restrictions apply to the allotted shares
- No share certificate numbers applicable (demat form)
- No listing fees payable for this issuance
- The disclosure has been uploaded on the company website at www.mankindpharma.com